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| INTRODUCTION
Endometrial cancer is the most commonly diagnosed gynecologic cancer in the United States with an estimated 61 380 new cases in 2017. The majority of endometrial cancers are type I cancers. Type I tumors are often diagnosed at an early stage and tend to have an overall favorable prognosis. However, a proportion of women will be diagnosed with a more aggressive histologic subtype referred to as type II uterine cancer. This historical classification is useful but there is heterogeneity and overlap between the groups. In particular when considering grade 3 endometrioid tumors, there is a challenge with pathologic accuracy due to poor diagnostic reproducibility. 1 Type II or high-grade uterine cancer affects approximately 20%-30% of women with endometrial cancer and is associated with a far greater risk of recurrence and an increased overall mortality. 1 It is estimated that 10 920 deaths will be attributed to endometrial cancer in 2017, with the majority of these deaths due to the aggressive high-grade uterine cancers.
2
The diagnosis of endometrial cancer in the black population can carry a substantially higher mortality in comparison with their white, Hispanic, and Asian counterparts. The age-adjusted incidence of endometrial cancer has been reported to be 31% lower among black patients compared to white women; however, the age-adjusted mortality among black women is approximately 84% higher. 3 Many of the prior studies on disparity in endometrial cancer outcomes including those that have analyzed genetic and molecular tumor features are limited and omit additional confounding variables such as socioeconomic factors, time interval from diagnosis to treatment, type of intervention, and comorbid conditions. We sought to examine factors contributing to inequality in outcomes among racial groups diagnosed with high-grade uterine cancers by analyzing data from the California Cancer Registry (CCR).
| METHODS
Data were obtained from the California Cancer Registry (CCR). The CCR is a state-mandated registry that has collected data on all cancers diagnosed in residents of the state since 1988. The CCR is comprised of three regional registries that are members of the National Cancer Institute's (NCI) Surveillance Epidemiology and End Results (SEER) program. The CCR extracts information on patient demographics, tumor characteristics, and treatment. Vital status information is routinely updated through regular linkages with state and national databases as well as active hospital follow-up.
| Study population and eligibility
We obtained data on all women (age ≥18) diagnosed with invasive endometrial cancers from 1998 to 2009, excluding those diagnosed by death certificate or autopsy only (N = 47 131; Figure 1 ). We further restricted our selection to high-grade endometrial cancers based on International Classification of Diseases for Oncology, Third edition (ICD-O-3) morphology codes, detailed below (N = 12 650).
Patients with a prior cancer diagnosis within 5 years of the tumor of interest (N = 762), those with incomplete dates of diagnosis (N = 1005) or incomplete follow-up (N = 15), or with missing treatment dates (N = 138) were excluded. The cohort was further limited to non-Hispanic white, nonHispanic black, Hispanic, and non-Hispanic Asian/Pacific Islanders (PI).
The 
| Measures
SEER does not extract International Federation of Gynecology and Obstetrics (FIGO) stage directly. We derived the FIGO stage using data on tumor extension, lymph node involvement, and presence of metastases. The CCR does not collect data on individual-level measures of socioeconomic status (SES). A previously described composite measure was used to assign each case to a quintile of neighborhood SES (nSES) based on the Census block group of the geocoded address at the time of diagnosis. 5, 6 A Charlson Index derived from linkage of CCR data with statewide hospital discharge data was available from CCR and was used as a measure comorbidity burden. 7 Scores were categorized as 0 (no comorbidity), 1, and 2 or higher.
Time to treatment was calculated in days from the date of diagnosis to the date of definitive surgery (hysterectomy), radiation, or chemotherapy, which ever was the earliest. Time to treatment was categorized as ≤2 weeks, 2-4 weeks, and >4 weeks.
| Statistical methods
The association of patient and tumor characteristics with time to initiation of treatment was modeled using multinomial logistic regression. Variables included in the model were selected a priori and included race/ethnicity, age, stage, histologic subtype, type of treatment first received, insurance status, nSES, marital status, NCI cancer center status, and year of diagnosis. Two to four weeks to treatment was used as the referent category.
Disease-specific survival analysis was conducted. To ensure a minimum five-year potential follow-up for the survival analysis, only cases diagnosed between 1998 and 2009 were included (N = 10 647). Survival time was calculated in days from date of diagnosis to date of death or last contact. Vital status data were complete through 31 December 2014. Any patient alive at this date was censored at this time. For disease-specific survival analysis, patients who died from a cause other than uterine cancer were censored on the date of death. Using the Kaplan-Meier method, we described disease-specific survival. Survival by stage, race/ethnicity, and time to treatment category was compared using the log-rank test. The associations of race/ethnicity with disease-specific survival was modeled using Cox proportional hazards regression. Covariates were selected a priori and included age, histologic subtype, stage, time to treatment, type of treatment, nSES, NCI cancer center, and year of diagnosis. Proportional hazards assumptions were tested using Schoenfeld residuals and log-log plots.
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Tests were two-sided, with P < 0.05 considered statistically significant.
| RESULTS
Our study included 10 647 patients who met the eligibility criteria for survival analysis. Median follow-up was 9.1 years for nondeceased patients (interquartile range: 6.8-12.3 years).
| Characteristics of entire cohort
The majority of patients in this cohort of high-grade endometrial cancer were non-Hispanic (NH) white (64.1%), followed by Hispanic (15.7%), Asian (10.4%), and NH black (9.8%). Most patients were diagnosed between the age of 50 and 79 (75.6%), with 8.4% <50, and 16.0% eighty or older. High-grade endometrioid adenocarcinoma was the most common histologic subtype (43.9%), followed by serous (17.6%), carcinosarcoma (17.2%), mixed (16.0%), and clear cell (5.2%). Most patients were diagnosed at stage I (44.4%), followed by stage III (23.5%), stage IV (19.0%), stage II (9.3%), and unknown (3.9%). About 36.1% of patients received radiation, while 27.8% received chemotherapy. Most patients were reasonably healthy with Charlson Comorbidity Index (CCI) of 0 (62.6%). Approximately 14.2% of patients were in the lowest quintile of neighborhood socioeconomic status (nSES), and 23.8% were among highest SES. Approximately half of the patients had private insurance (51.2%), followed by Medicare (31.1%), and Public/ Medicaid, VA (12.1%).
| Comparisons of patient characteristics and outcomes by race/ethnicity
NH black women had higher incidence of certain aggressive histologic subtypes in comparison with NH whites, including serous carcinoma (24.4% vs 16.3%, P < 0.0001) and carcinosarcoma (24.9% vs 16.0%, P < 0.0001; Table 1 ). NH white patients were more likely to have stage I disease compared to NH black women (45.8% vs 34.9%, P = 0.0001). NH black women were less likely to have a lymph node dissection compared to NH white patients (P < 0.0001). Also among patients who had lymph node dissections, NH white patients were more likely to have 10 or greater lymph nodes removed compared to NH black patients (P = 0.0044). NH black women were more likely to reside in the lowest nSES (30.2) %, compared to 8.4% of NH white women (P < 0.0001; Table 1 ).
In the multivariable model, compared to NH white, patients who are Hispanic and NH black were more likely to receive care greater than 4 weeks vs within 2-4 weeks from diagnosis (Odds ratio (OR) 1.28, CI:1.10-1.49, OR 1.40, CI: 1.17-1.68, respectively). There was an association of increasing age with receipt of treatment later than 4 weeks (OR 1.01, CI: 1.00-1.01, per year of age). Women with CCI score of 1 or 2 were more likely to receive later treatment than women with no significant health issue (OR 1.31, CI: 1.15-1.48, OR 1.23, CI: 1.03-1.47, respectively). NH black patients were more likely to have a CCI score of 2 or greater compared to their counterparts in the other racial groups (Table 1) .
Women from neighborhoods in the lowest quintile of SES were almost twice as likely to receive later treatment than those from the highest quintile of neighborhood SES (OR 1.93, CI: 1.61-2.31). Compared to women with private insurance, those with no insurance and those with Medicaid or VA were almost twice as likely to be treated later than 4 weeks from diagnosis vs 2-4 weeks (OR 1.94, CI: 1.30-2.89 and OR 1.74, CI: 1.45-2.09), respectively) (data not shown).
Non-Hispanic black patients had a worse 5-year diseasespecific survival (DSS) when compared to other racial/ethnic groups (Figure 2 ). The five-year DSS for NH black women was 54% (51-57%), compared to NH white women 66% (65-67%), Hispanic 67% (64-69%) and Asians 69% (67-72%) (P < 0.0001).
3.3 | The effect of time to treatment on disease-specific survival by race/ethnicity and by histologic subtype When DSS was stratified by race within time to treatment, NH black patients did not have a worse DSS when treated within 2 weeks from diagnosis, based on Kaplan-Meier analysis (P = 0.1795; Figure 3) .
However, when time to treatment was between 2 and 4 weeks or greater than 4 weeks, NH black patients had a significantly worse DSS compared to patients of other race/ ethnicity (P < 0.0001, P < 0.0001, respectively; Figure 3 ). All women regardless of race, treated at less than or equal to 2 weeks' time from diagnosis to intervention had a poorer outcome compared to their counterparts who received treatment between 2 and 4 weeks or greater than 4 weeks from diagnosis (data not shown). Patients treated in the ≤2 weeks interval were more likely to have a diagnosis of carcinosarcoma compared to high-grade endometrioid (HR 1.41, 95% CI 1.24-1.60). Patients treated in this time frame were also more likely to be stage III compared to stage I and more likely to be stage IV vs stage I, (HR 1.18, 95% CI 1.05-1.34, and HR 2.67, 95% CI 2.35-3.03, respectively) (data not shown).
| Multivariable model of associations with disease-specific survival
Using Cox proportional hazard multivariable analysis, after adjusting for age, histologic subtype, type of treatment, time to treatment, comorbidity, insurance status, socioeconomic status, marital status, NCI cancer center, and year of diagnosis, NH black women still had an increased hazard of diseasespecific death compared to NH white women (HR 1.21, 95% CI 1.09-1.35; Table 2 ).
In the multivariate analysis, stage at diagnosis had the greatest effect on disease-specific survival. Women diagnosed with stage IV disease had a ten-fold greater risk of disease-specific mortality compared to those diagnosed at stage I (HR 10.39, CI: 9.35-11.55). Age appeared to play a significant role with a 2% increased risk of death of disease per year of age. Patients with carcinosarcoma had an increased risk of disease-specific death compared to patients with high-grade endometrioid carcinoma (HR 1.88, CI: 1.74-2.27), whereas those with mixed histology had a decreased hazard of disease-specific mortality compared to those with high-grade endometroid histology (HR 0.68, CI: 0.61-0.77). Patients who were treated within the first 2 weeks after diagnosis had an elevated risk of disease-specific death compared to those treated between 2 and 4 weeks after diagnosis (HR 1.14, CI: 1.03-1.25), but interestingly there was no significant association with disease-specific mortality for greater than 4 weeks from diagnosis to treatment. Notably, patients with a diagnosis of carcinosarcoma had a worse 5-yr DSS within each time to treatment category (≤2 weeks, 2-4 weeks, and > 4 weeks).
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F I G U R E 2
Patients with more comorbid conditions (CCI 1 or 2 + ) were more likely to die of disease compared to their peers with CCI 0. Compared to patients with private insurance, those with Medicare had an elevated risk of disease-specific death (HR 1.09, CI: 1.01-1.18). Treatment at a NCI cancer center was associated with lower risk of disease-specific death (HR 0.88, CI 0.79-0.97; Table 2 ).
We also evaluated the association of race/ethnicity with disease-specific survival by histologic subtype in multivariable model stratified by stage and adjusted for age, treatment (hysterectomy, chemotherapy, radiation), time to treatment, Charlson comorbidity score, primary payer, neighborhood SES, marital status, care at NCI-designated cancer center, and year of diagnosis. NH black patients compared to NH white T A B L E 2 Associations with disease-specific survival (hazard ratios and 95% confidence intervals) patients have an increased hazard for death even within some of the less favorable subtypes. Specifically, the elevated hazard ratios were found for patients with carcinosarcoma, serous, and mixed subtypes. There was no significant difference for clear cell or high-grade endometrioid histology (data not shown).
| DISCUSSION
Although Latinos and African Americans comprise approximately 30% of the population in the USA, these patients account for just about 6% of those enrolled in federally funded clinical trials. 8 Racial/ethnic minority groups including Native Hawaiians, Asian Americans, American Indians, and PI were found to be significantly underrepresented in cancer clinical trials. Also less than 2% of these government-funded cancer research studies looked at minority health needs. 9 This in itself may explain the worse outcomes for minority groups such as NH black patients when treated using the same treatment paradigms recommended based on superiority in clinical trials; however, these trials likely include populations that may have been largely socially and genetically different. Racial disparities in care and outcomes are pervasive in medicine and not only in the field of oncology. Race differences also exist in the performance of potential life-saving interventions, such as invasive cardiac procedures. 10 There is no doubt that the reasons behind these observations are complex. In our review of high-grade uterine cancers in the CCR, the mortality of high-grade endometrial cancer varies greatly across all racial/ethnic groups. Specifically, NH black women have an overall poorer prognosis compared to all other racial groups. This extreme differentiation in an already poor prognosis group of endometrial cancer patients is multifactorial. Factors that may serve to contribute to such differences include molecular/ genetic differences, socioeconomic, access to specialized centers, time to treatment, and type of treatment received. The survival disparity is highlighted when evaluating the socioeconomic differences across the various racial groups. In our database study, NH black women were more likely to reside in the lowest nSES 30.5%, compared to 8.3% of NH white women and were more likely to be unmarried and enrolled in a government-sponsored insurance program compared NH white patients. Lower socioeconomic status and lack of healthcare funding may explain some of the inequalities in definitive treatment for this patient population. Compared to NH white, patients who are Hispanic and NH black were more likely to receive care greater than 4 weeks vs within 2-4 weeks from diagnosis although this treatment delay did not significantly affect outcome in this study of high-risk endometrial cancer. NH black and Hispanic patients may have delays in receiving treatment due to lack of access to appropriate tertiary care centers, long waiting periods for enrollment into government-sponsored programs and further delay with awaiting appointment scheduling.
These effects are often difficult to quantify given that individual factors cannot be appropriately teased out from a large database study. These data may become more important when assessing factors affecting outcomes in less aggressive conditions than high-grade uterine cancers.
Non-Hispanic black patients compared to NH white patients accounted for 9.8% vs 64.1% of this study population, respectively, even though according to the 2015 United States Census Bureau estimates, California's population was 6.5% black and 72.9% white. In general, NH black women present more commonly with aggressive subtypes of endometrial cancer and at a more advanced stage. In our study, the incidence of all aggressive histologic subtypes of high-grade endometrial cancers remained higher in the NH black population as well: serous (23.8% vs 15.4%), clear cell (5.9% vs 4.8%), and carcinosarcoma (24.5% vs 15.1%).
Molecular differences between endometrial cancers in NH black and NH white women has been studied previously and included identifying differences in p53 mutations, Her2/neu expression, and PTEN mutations. Mutations in tumor suppressor gene p53 are associated with overall poorer prognosis. Alkushi Both mutation and somatic copy number alteration revealed a significant amount of TP53 mutations in black patients. It was also noted that there was a significantly higher frequency of somatic mutations in DNA mismatch repair genes in the tumors of Asian patients. 13, 14 These molecular differences between racial groups likely also contribute to the varying disease response to treatment and to some of the disparity in health care outcomes. As such there may be a need for less discriminate genetic or molecular testing to determine risk and guide therapy among the racial/ethnic groups. Future research is needed, however, to explain the molecular differences in carcinogenesis and treatment responses within racial/ethnic groups. The observation of a timely diagnosis and receipt of appropriate care are also important factors when assessing for healthcare disparities. In our review, we found that NH white women are more likely to present with early stage disease, undergo a hysterectomy, and have a lymphadenectomy performed (10 or more nodes), as compared to NH black women. There were, however, no significant differences found in the receipt of adjuvant therapies between these two groups. We also found that women, treated at a less than or equal to 2-week time from diagnosis to intervention had a poorer outcome compared to their counterparts who received treatment between 2 and 4 weeks from diagnosis or later. Factors that may account for this difference include the presence of an aggressive/faster growing histologic diagnosis such as carcinosarcomas warranting sooner intervention, with an overall poor prognosis or more symptomatic patients with larger volume disease requiring earlier management. More late stage patients also received surgery in the less than 2-week interval.
Our study is not without limitations, due to the retrospective nature of our study, decisions regarding surgery, type of adjuvant treatment, and timing were likely confounded by other factors. The registry may not completely capture all treatment data, especially treatment that is performed in the outpatient setting; however, in our cohort, treatment data were available for 95% of the population. In addition, the database does not include information pertaining to the specifics of provider level of training, expertise, treatment decisions, type of chemotherapy received, extent of residual disease after surgery, molecular profiling data, and completion rates of for example chemotherapy or radiation. Also provider factors including provider beliefs, biases, and expectations cannot be accounted for with a database study. The California Cancer Registry like other databases is subject to potential reporting errors although validation of data accuracy is carried out as best as is possible by internal monitoring and communication with reporting sites.
Despite the limitations, we think this study highlights the stark differences in prognosis and outcomes for NH black women diagnosed with high-grade endometrial cancers. The drivers for worse outcomes among NH black patients may include limitations in access to care as well as intrinsic factors that are still unexplained. Given the steep rise in endometrial cancer rates, it is imperative to continue investigations into the main drivers of this racial gap in order to provide optimal cancer treatments for minority groups.
Increasing the awareness of patients and healthcare professionals of the signs and symptoms of uterine cancer and the differences in tumor type distribution among ethnic groups may also help reduce the survival difference by prompting earlier referral to subspecialty care. With the increased awareness and concern around ethnic/racial disparities in the care and outcomes of endometrial cancer patients, organizations such as Society of Gynecologic Oncologists (SGO) are championing efforts to eliminate disparities. There will be also the development of the Endometrial Cancer Action Network for African-Americans (ECANA) to foster patientcentered research in endometrial cancer disparities. The complex issue of healthcare disparity requires a multi-pronged approach addressing patient, providers, and system factors.
